New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2013
10:06 EDTBKH, ADTN, CFR, PNFP, JBT, NVO, KMB, CCL, ACT, CHK, IP, TEVA, NTI, CNP, ABC, MU, CMA, PKG, PGR, SJMOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Actavis (ACT) downgraded to Market Perform from Outperform at Wells Fargo... Adtran (ADTN) downgraded to Neutral from Buy at Mizuho... AmerisourceBergen (ABC) downgraded to Neutral from Buy at UBS... Black Hill (BKH) downgraded to Sector Perform from Outperform at RBC Capital... Carnival (CCL) downgraded to Neutral from Outperform at Exane BNP Paribas... CenterPoint Energy (CNP) downgraded to Underperform from Neutral at Credit Suisse... J.M. Smucker (SJM) downgraded to Sell from Neutral at Goldman... Kimberly Clark (KMB) downgraded to Sell from Neutral at Goldman... Northern Tier (NTI) downgraded to Hold from Buy at Dahlman Rose... Novo Nordisk (NVO) downgraded to Underweight from Neutral at JPMorgan... Progressive (PGR) downgraded to Underweight from Equal Weight at Evercore... Teva (TEVA) downgraded to Market Perform from Outperform at Wells Fargo... JBT Corporation (JBT) downgraded to Neutral from Buy at Sidoti... Packaging Corp. (PKG) downgraded to Underperform from Outperform at CLSA... International Paper (IP) downgraded to Outperform from Buy at CLSA... Pinnacle Financial (PNFP) downgraded to Market Perform from Outperform at Raymond James... Comerica (CMA) downgraded to Underperform from Market Perform at Raymond James... Cullen/Frost (CFR) downgraded to Underperform from Market Perform at Raymond James... Chesapeake (CHK) downgraded to Trim from Hold at Tudor Pickering... Micron (MU) downgraded to Negative from Neutral at Susquehanna.
News For ACT;ADTN;ABC;CCL;BKH;CNP;KMB;SJM;NTI;NVO;PGR;TEVA;JBT;PKG;IP;PNFP;CMA;CHK;CFR;MU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
February 17, 2015
15:54 EDTSJMJ.M. Smucker targets long-term EPS growth of 8% plus
Targets long term organic growth 3%-4%.
15:51 EDTSJMJ.M. Smucker share repurchase activity on hold in near time
Subscribe for More Information
15:32 EDTACTNotable companies reporting before tomorrow's open
Subscribe for More Information
13:52 EDTACTEarnings Preview: Actavis near 52-week high ahead of Q4 earnings report
Subscribe for More Information
13:18 EDTACTOmega Advisors gives quarterly update on stakes
Subscribe for More Information
11:24 EDTCHKMcClendon, American Energy say Chesapeake lawsuit 'baseless'
Subscribe for More Information
10:41 EDTCHKChesapeake files suit against founder McClendon, Reuters reports
Chesapeake Energy filed suit today alleging that its founder and former CEO, Aubrey McClendon, "misappropriated highly sensitive trade secrets" in order to launch his new venture American Energy Partners, Reuters reports. Reference Link
10:00 EDTMUOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:56 EDTMUMicron rises, levels to watch
Subscribe for More Information
09:21 EDTJBTJBT awarded $6M engineering contract form U.S. Navy
Subscribe for More Information
09:20 EDTJBTJBT Corporation awarded contracts totaling $20M from customers in Asia
Subscribe for More Information
08:47 EDTTEVABioTime provides update on Cell Cure's product development, partnering
BioTime (BTX) and its subsidiary Cell Cure Neurosciences provided an update on Cell Cure’s product development and partnering activities. On February 16, Cell Cure opened the clinical trial of OpRegen titled “Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients with Advanced Dry-Form Age-Related Macular Degeneration with Geographic Atrophy” at Hadassah University Medical Center in Jerusalem, Israel. Patient enrollment is expected to begin shortly. OpRegen consists of animal product-free retinal pigment epithelial cells with high purity and potency. On October 31, 2014, the FDA cleared Cell Cure's Investigational New Drug application to initiate the clinical trial of OpRegen in patients with the severe form of age-related macular degeneration with geographic atrophy.The Phase I/IIa clinical trial, will evaluate three different dose regimens of OpRegen. Following transplantation, the patients will be followed for 12 months at specified intervals, to evaluate the safety and tolerability of the product. Following the initial 12 month period, patients will continue to be monitored at longer intervals for an additional period of time. A secondary objective of the clinical trial will be to examine the ability of transplanted OpRegen to engraft, survive, and moderate disease progression in the patients. In addition to thorough characterization of visual function, a battery of ophthalmic imaging modalities will be used to quantify structural changes and rate of GA expansion. Cell Cure also announced that the option granted to Teva (TEVA) under a Research and Exclusive Option Agreement of October 7, 2010 to license-in rights to its OpRegen product has expired without having been exercised by Teva. Cell Cure will therefore be continuing the clinical development of OpRegen on its own and pursuing discussions with other potential strategic partners, including those that have already indicated interest in participating in development and commercialization of the product. Cell Cure also announced that US patent No. 8,956,866 relating to a proprietary method of manufacturing RPE cells is expected to issue on February 17. This patent combined with other patents and patent applications in the BioTime family of companies provides significant patent protection for this novel therapeutic modality for AMD.
08:39 EDTTEVATeva deal small but important, says BMO Capital
Subscribe for More Information
08:35 EDTTEVATeva announces launch of generic Lovenox and Zyvox in U.S.
Subscribe for More Information
08:17 EDTPKG, IPContainerboard bull Perry Capital trims stakes in RockTenn, KapStone
Subscribe for More Information
07:41 EDTMUMicron price target raised to $45 from $42 at Jefferies
Subscribe for More Information
07:15 EDTSJMConsumer Analyst Group of New York (CAGNY) to hold a conference
Subscribe for More Information
07:10 EDTMUMicron upgraded to Outperform from Neutral at Macquarie
Macquarie upgraded Micron to Outperform with a $40 price target based on expectations memory medium-term pricing trends will remain stable given structural supply constraints, which could result in $5B in free-cash-flow in CY16.
07:04 EDTTEVATeva, Eagle enter license agreement for EP-3102
Teva Pharmaceutical Industries (TEVA) and Eagle Pharmaceuticals (EGRX) announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle’s bendamustine hydrochloride rapid infusion product for the treatment of chronic lymphocytic leukemia and indolent B-cell non-Hodgkin lymphoma. Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30M and is eligible to receive up to $90M in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval. The companies will also settle the pending patent infringement action between them.
05:31 EDTADTNADTRAN receives extension of TL 9000 certification in R&D facility
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use